Gilead Sciences Enters Material Agreement, Creates Financial Obligation

Ticker: GILD · Form: 8-K · Filed: 2024-11-20T00:00:00.000Z

Sentiment: neutral

Topics: material-agreement, financial-obligation, debt

TL;DR

Gilead just signed a big deal and took on new debt/obligation. Watch this space.

AI Summary

On November 20, 2024, Gilead Sciences, Inc. entered into a material definitive agreement, likely related to financing or a significant transaction. This filing also indicates the creation of a direct financial obligation or an off-balance sheet arrangement for the registrant. The company is based in Foster City, California.

Why It Matters

This filing signals a significant financial move by Gilead Sciences, potentially impacting its balance sheet and future financial obligations.

Risk Assessment

Risk Level: medium — The creation of a direct financial obligation or off-balance sheet arrangement can introduce new financial risks and complexities for the company.

Key Players & Entities

Gilead Sciences, Inc. (company) — Registrant
November 20, 2024 (date) — Date of earliest event reported
Foster City, California (location) — Principal Executive Office Location

FAQ

What is the nature of the material definitive agreement entered into by Gilead Sciences, Inc. on November 20, 2024?

The filing indicates the entry into a material definitive agreement, but the specific details of the agreement are not provided in this excerpt.

What type of financial obligation has Gilead Sciences, Inc. created?

The filing states the creation of a direct financial obligation or an obligation under an off-balance sheet arrangement of a registrant.

Where are Gilead Sciences, Inc.'s principal executive offices located?

Gilead Sciences, Inc.'s principal executive offices are located at 333 Lakeside Drive, Foster City, California.

What is the Commission File Number for Gilead Sciences, Inc.?

The Commission File Number for Gilead Sciences, Inc. is 0-19731.

What is the IRS Employer Identification Number for Gilead Sciences, Inc.?

The IRS Employer Identification Number for Gilead Sciences, Inc. is 94-3047598.

From the Filing

0001104659-24-121025.txt : 20241120 0001104659-24-121025.hdr.sgml : 20241120 20241120161536 ACCESSION NUMBER: 0001104659-24-121025 CONFORMED SUBMISSION TYPE: 8-K PUBLIC DOCUMENT COUNT: 18 CONFORMED PERIOD OF REPORT: 20241120 ITEM INFORMATION: Entry into a Material Definitive Agreement ITEM INFORMATION: Creation of a Direct Financial Obligation or an Obligation under an Off-Balance Sheet Arrangement of a Registrant ITEM INFORMATION: Other Events ITEM INFORMATION: Financial Statements and Exhibits FILED AS OF DATE: 20241120 DATE AS OF CHANGE: 20241120 FILER: COMPANY DATA: COMPANY CONFORMED NAME: GILEAD SCIENCES, INC. CENTRAL INDEX KEY: 0000882095 STANDARD INDUSTRIAL CLASSIFICATION: BIOLOGICAL PRODUCTS (NO DIAGNOSTIC SUBSTANCES) [2836] ORGANIZATION NAME: 03 Life Sciences IRS NUMBER: 943047598 STATE OF INCORPORATION: DE FISCAL YEAR END: 1231 FILING VALUES: FORM TYPE: 8-K SEC ACT: 1934 Act SEC FILE NUMBER: 000-19731 FILM NUMBER: 241480589 BUSINESS ADDRESS: STREET 1: 333 LAKESIDE DR CITY: FOSTER CITY STATE: CA ZIP: 94404 BUSINESS PHONE: 6505743000 MAIL ADDRESS: STREET 1: 333 LAKESIDE DR CITY: FOSTER CITY STATE: CA ZIP: 94404 FORMER COMPANY: FORMER CONFORMED NAME: GILEAD SCIENCES INC DATE OF NAME CHANGE: 19930328 8-K 1 tm2426602d4_8k.htm FORM 8-K false 0000882095 0000882095 2024-11-20 2024-11-20 iso4217:USD xbrli:shares iso4217:USD xbrli:shares       UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549       FORM 8-K       CURRENT REPORT Pursuant to Section 13 or 15(d) of The Securities Exchange Act of 1934   DATE OF REPORT (DATE OF EARLIEST EVENT REPORTED): November 20, 2024       GILEAD SCIENCES, INC. (Exact name of registrant as specified in its charter)   Delaware 0-19731 94-3047598 (State or Other Jurisdiction of Incorporation) (Commission File No.) (IRS Employer Identification No.)   333 Lakeside Drive , Foster City , California (Address of Principal Executive Offices)   94404 (Zip Code)   ( 650 ) 574-3000 (Registrant’s Telephone Number, Including Area Code)   Not Applicable (Former name or former address, if changed since last report)   Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:   ¨      Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)   ¨      Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)   ¨      Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))   ¨      Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))   Securities registered pursuant to Section 12(b) of the Act:   Title of each class   Trading Symbol(s)   Name of each exchange on which registered Common Stock, par value $0.001 per share   GILD   The Nasdaq Global Select Market   Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§240.12b-2 of this chapter).   Emerging growth company ¨   If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ¨           Item 1.01. Entry into a Material Definitive Agreement.   Supplemental Indenture   On November 20, 2024, Gilead Sciences, Inc. (the “Company”) and Computershare Trust Compan